Enzo Biochem, Inc. (NYSE:ENZ) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $3.74 and last traded at $3.80, with a volume of 5285 shares traded. The stock had previously closed at $3.88.

Separately, ValuEngine upgraded Enzo Biochem from a “sell” rating to a “hold” rating in a report on Monday, July 16th.

Several large investors have recently bought and sold shares of ENZ. A.R.T. Advisors LLC bought a new position in shares of Enzo Biochem during the first quarter worth about $115,000. Hartford Investment Management Co. bought a new position in shares of Enzo Biochem during the second quarter worth about $118,000. Highbridge Capital Management LLC grew its holdings in shares of Enzo Biochem by 50.3% during the first quarter. Highbridge Capital Management LLC now owns 38,340 shares of the medical research company’s stock worth $210,000 after buying an additional 12,836 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of Enzo Biochem during the second quarter worth about $324,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Enzo Biochem during the second quarter worth about $400,000. Institutional investors and hedge funds own 67.75% of the company’s stock.

Enzo Biochem Company Profile (NYSE:ENZ)

Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.

Recommended Story: Initial Public Offering (IPO)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.